Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Telomir Pharmaceuticals, Inc. - Common Stock (NQ:TELO)

1.995 +0.025 (+1.27%)
Streaming Delayed Price Updated: 2:16 PM EDT, Jun 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 157,331
Open 1.950
Bid (Size) 1.990 (2)
Ask (Size) 2.000 (2)
Prev. Close 1.970
Today's Range 1.910 - 2.000
52wk Range 1.870 - 8.400
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Preclinical Breakthrough with Telomir-1 in Wilson’s Disease Model
Via Investor Brand Network
Telomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease Model
Via ACCESS Newswire

Performance

YTD
-51.0%
-51.0%
1 Month
-20.5%
-20.5%
3 Month
-59.6%
-59.6%
6 Month
-60.9%
-60.9%
1 Year
-63.7%
-63.7%

More News

Read More
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Preclinical Breakthrough in Age-Reversal Model With Telomir-1
Via Investor Brand Network
These stocks are moving in today's pre-market session
Via Chartmill
Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome
Via ACCESS Newswire
EXCLUSIVE: Telomir Pharmaceuticals Lead Drug Shows Promising Signs In Animal Study For Rare Premature Aging Disorder
Via Benzinga
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) to Pursue Partnerships at BIO 2025 as IND Prep for Telomir-1 Advances
Via Investor Brand Network
Exposures Product Safety
Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform
Via ACCESS Newswire
These stocks that are showing activity before the opening bell on Monday.
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Vision Restoration and Retinal Regeneration in Preclinical AMD Study
Via Investor Brand Network
Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints
Via ACCESS Newswire
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Secures $3M Equity Investment to Advance Age-Reversal Pipeline
Via Investor Brand Network
Telomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease IND
Via ACCESS Newswire
EXCLUSIVE: Telomir Pharma To Raise $3 Million Via Equity Financing To Fund Its Rare Disease IND
Via Benzinga
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Unveils Breakthrough Silver(II) Antimicrobial Drug Candidate Telomir-Ag2
Via Investor Brand Network
Telomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market Opportunity
Via ACCESS Newswire
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Unveils Preclinical Data Supporting Expansion into Autism and Rare Neurological Disorders
Via Investor Brand Network
Exposures Product Safety
Telomir Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in Human Cell Lines Supporting Therapeutic Potential in Autism and Spasmodic Dysphonia
Via ACCESS Newswire
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Preclinical Success of Telomir-1 in Prostate Cancer Model
Via Investor Brand Network
Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells
Via ACCESS Newswire
Telomir Pharmaceuticals Lead Drug Candidate Inhibits Tumor Growth In Aggressive Prostate Cancer Cells, Animal Study Shows
Via Benzinga
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Reports Preclinical Success in Age-Reversal Science with Telomir-1
Via Investor Brand Network
Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines
Via ACCESS Newswire
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Stabilizes Silver(II) for Advanced Medical Applications
Via Investor Brand Network

Frequently Asked Questions

Is Telomir Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Telomir Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Telomir Pharmaceuticals, Inc. - Common Stock trade on?
Telomir Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Telomir Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Telomir Pharmaceuticals, Inc. - Common Stock is TELO on the Nasdaq Stock Market
What is the current price of Telomir Pharmaceuticals, Inc. - Common Stock?
The current price of Telomir Pharmaceuticals, Inc. - Common Stock is 1.995
When was Telomir Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Telomir Pharmaceuticals, Inc. - Common Stock was at 06/12/25 02:16 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.